Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Status:
Completed
Trial end date:
2017-12-28
Target enrollment:
Participant gender:
Summary
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to
metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial
flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic
receptor.